Skip to main content
. 2010 Sep 8;2010(9):CD008418. doi: 10.1002/14651858.CD008418.pub2

Comparison 3. Formoterol versus short‐acting beta2‐agonists (background LABA use).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Patients with a serious adverse event (all‐cause) 6 21863 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.81, 1.09]
1.1 Maintenance LABA 3 8319 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.68, 1.03]
1.2 No maintenance LABA 4 13544 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.86, 1.30]